Skip to main content
. 2023 Jan 10;13:1063002. doi: 10.3389/fimmu.2022.1063002

Figure 8.

Figure 8

Fab binding activity of anti-EGFR/HER2 BsAb. (A) Schema of dual-binding ELISA format that was used in this study. (B) The anti-EGFR/HER2 BsAb shows dose-dependent binding consistent with its proposed quaternary structure. (C) Schema of direct HER2 binding ELISA. (D) The binding affinity of BsAb was compared to pertuzumab.The error bars indicate standard deviation from three independent experiments. Graphs were generated using GraphPad Prism version 8.4.3 for Windows.